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Derivation of a Calculation Formula for Breakpoints of Antimicrobial Agents in
Urinary Tract Infections
Soichi Arakawa, * Takashi Matsui, Sadao Kamidono, Yukimichi Kawada, Hiromi Kumon,
Keiji Hirai, Takaoki Hirose, Tetsuro Matsumoto, Keizo Yamaguchi, Tadashi Yoshida,
Kunitomo Watanabe, Kazue Ueno, Atsushi Saito, and Takashi Teranishi
The Study Group of the Japan Society of Chemotherapy for Measuring Sensitivity ofAntimicrobial Agents
The regression coefficients affecting the pharmacokinetic parameters of the breakpoints of antimicrobial
agents (ie, empiric breakpoints) obtained retrospectively from clinical trial data were considered, and the
pharmacokinetic parameters that w~re thought to strongly correlate to the empiric breakpoints were se-
lected. The regression coefficients of the selected pharmacokinetic parameters were estimated, based on
the categoric regression analysis. Estimated regression coefficients were rounded, and breakpoints were
constructed using these rounded values. The breakpoint for complicated cystitis was determined, and it was
decided that to obtain the breakpoint of complicated pyelonephritis, one tube (ie, one-half value) would be
subtracted from the breakpoint of complicated cystitis, as calculated using the formula.
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INTRODUCTION
The following 3 factors are taken into consideration
when selecting an antimicrobial agent to treat an infec-
tious disease: the MIC against the causative bacteria,
the drug concentration in the infectious focus when a
standard dosage of the drug is administered, and the
patient's resistance to infections (immunologic potency).
Once the MICs of candidate antimicrobial agents are
known, we can decide on a suitable antimicrobial agent,
based on the patient's status and the pharmacokinetics
of the agent. Currently, in medical therapies for urinary
tract infections, the antimicrobial agent has been selected
on the basis of a vague assumption of its efficacy de-
rived from the general urinary system distribution of
the agent. The breakpoint MIC is a simple borderline
value for a more scientific selection of a drug in actual
clinical practice, where a quick judgment is demanded.
Generally speaking, the breakpoint MIC is defined as
the MIC for which a clinical effect is expected at a high
rate (> 80%) for bacteria against which the MIC of a
given drug is lower than the breakpoint. In other words,
a drug with a higher breakpoint MIC would have a wider
range of MICs that could be expected to show efficacy.
The Study Group of the Japan Society of Chemo-
therapy for Measuring Sensitivity of Antimicrobial
Agents (for urinary tract infections; chairman: Sadao
Kamidono) has constructed a formula to calculate break-
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points of antimicrobial agents for complicated urinary
tract infections. The breakpoint of each antimicrobial
agent was calculated on the basis of the outcomes of
comparative clinical trials (we refer to this as the em-
piric breakpoint hereafter).Then this empiric breakpoint
was characterized by pharmacokinetic parameters. Fi-
nally, a formula was derived to estimate the empiric
breakpoint by combining typical parameters (from here
on, the breakpoint estimated by the formula is referred
to as the predicted breakpoint).
We reported the method for setting up the empiric
breakpoints in our first report.! In this paper, we present
the predicted breakpoints of antimicrobial agents for
complicated urinary tract infections on the basis of the
formula derived theoretically, using statistical techniques
together with discussion on various problems arising in
setting the formula.
MATERIALS AND PHARMACOKINETIC PARAMETERS
Materials
Based on the comparative clinical trials of oral and
parenteral intravenous antimicrobial agents for compli-
cated urinary tract infections, whose results were pub-
lished in the Journal ofthe Japan Society ofChemotherapy
in the past 10 years, 48 antimicrobial agents were se-
lected. There were 8635 eligible cases for analysis. For
details of the respective drugs, refer to our first report. I
Pharmacokinelic parameters
Seven pharmacokinetic parameters obtained in phase I
clinical trials of the 48 antimicrobial agents with the sin-
97Open access under the Elsevier OA license.
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gle administration of ordinary dosages were used. The
mean values for the agents were adopted as their phar-
macokinetic parameters.The 7 pharmacokinetic param-
eters are as follows: maximum blood concentration
(Cmax)' half-life (TlIz)' area under the curve (AUC), pro-
tein binding rate (Protein), maximum urinary concen-
tration (Uma), I-day cumulative urinary excretion (UV),
and UmajCmax (Utr).
Statistical analysis
Selection of pharmacokinetic parameters. Correlations
among the pharmacokinetic parameters and regressions
of empiric breakpoints I on the pharmacokinetic param-
eters were examined. Then the parameters with a rela-
tively strong association with the empiric breakpoint were
selected.
Derivation of the formula to calculate empiric break-
points. Based on categoric regression analysis (Hayashi's
quantification method),Z regression coefficients of the
above pharmacokinetic parameters were estimated. Es-
timated regression coefficients were rounded and break-
points were constructed using these rounded values.
Then, we examined performances of the breakpoints of
antimicrobial agents individually.
RESULTS OF ANALYSES
Formula to calculate breakpoints ofantimicrobial
agents for complicated cystitis
Selection ofpharmacokinetic parameters. To select phar-
macokinetic parameters that were relevant to the em-
piric breakpoints of antimicrobial agents, correlation
coefficients of the pharmacokinetic parameters with the
empiric breakpoints were determined. Those that
showed strong correlati9n were explored. In this analy-
sis, 6 drugs (cefsulodin, cefclidin, sulbactam/cefopera-
zone, cefmetazole, cefminox, and arbekacin) were
eXcluded from the 48 drugs due to reasons such as: small
numbers of cases whose baseline MIC was measured,
all the eradication rates with respect to the baseline MIC
were lower than 80% and empiric breakpoints (for com-
plicated cystitis) could not be established, and with-
drawal of the NDA (new drug application). Moreover,
11 drugs among the 42 drugs (Table 1) were judged
ineligible for evaluation because some of the pharma-
cokinetic parameters were missing. Among the 7 param-
eters, Protein was excluded because the protein values
were available only for 24 drugs. Consequently, 31 drugs
and 6 parameters remained to be examined. A correla-
tion matrix (Table 2) between these pharmacokinetic
parameters, MICso in the clinical trials, daily dose, and
the empiric breakpoints were examined.Then, the phar-
macokinetic parameters related to concentration (ie,
C max' AUC, U max' UV, and Utr) and the empiric break-
points, were subjected to log transformation.
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All the correlation coefficients among the following
5 parameters, that is, C max' AUC, U max' UV, and daily
dose, were higher than 0.7, indicating a strong relation-
ship among them. Umax was selected as a representative
parameter of the 5, because Umax showed the highest
correlation coefficient with the empiric breakpoint (cor-
relation coefficient: 0.582, and contribution ratio:
33.9%). In addition to U max ' T 1/Z and MICso were se-
lected as parameters to be examined because TI/2 was
not correlated with the above 5 parameters and MICso
was a direct parameter for antimicrobial activity.
Formula to calculate breakpoints. First, to construct a cal-
culation formula for breakpoints of antimicrobial agents,
categoric regression analysis was performed using 4 pa-
rameters, 2 pharmacokinetic parameters selected above
(Umax' and TI/2)' MICso and drug profile, as explanatory
variables, and the empiric breakpoint as response. U max'
T 1/Z' and MICso were categorized. Namely, TI/2 (hour) was
divided into 3 categories « 1, < 2, ~ 2 ), U max (.Ug/mL)
into 5 « 100, <3 00, < 1000, < 3000, ~ 3000) and MICso
(.Ug/mL) into 2 « 50, ~ 50), respectively. Two types of
classification with drugs (drug profile), type A and type B,
were established. Type A consisted of 2 divisions, 1 for
parenteral drugs and the other for orally administered
drugs.Type B consisted of3 divisions, 1 each for parenteral
drugs, oral quinolones and oral cephem drugs. Partial
correlation coefficient and range were high in Umax and in
the drug profile for both classification, type A and type B,
and it was shown that these 2 parameters particularly con-
tributed to empiric breakpoints (Table 3). In the exami-
nation with respect to the sign and size of the U max
coefficient, the greater the Umax was, the higher the esti-
mated empiric breakpoint became. With respect to the
drug profile, empiric breakpoints tended to be low for oral
drugs and high for parenteral drugs.
Next, the formula to predict an empiric breakpoint
for each drug was obtained through examination of the
estimated regression coefficients in the categoric regres-
sion analysis. To simplify this prediction formula, the
estimated regression coefficients were replaced with their
rounded values, the estimated regression coefficients
were exponentially transformed, and the transformed
coefficients were replaced with their rounded values in
0.5 increments (Table 4). For example, 0.5 was assigned
as a rounded value to the regression coefficient of the
category corresponding to "< 1" of TliZ in type A, which
was actually 0.711. The rounded value for MICso was
1.0 in both categories, irrespective of type A or Band,
consequently, it did not contribute to the prediction for-
mula in type A or B.Therefore, the MICso was excluded
from the parameters selected for determination of a pre-
diction formula.
Predicted breakpoints ofthe respective antimicrobial
agents were evaluated using the rounded values. The
results are shown in column 4 (type A) and column 6
(type B) ofTable 5. For example, the method to predict
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Table 1. Pharmacokinetic parameters and MIC80 of each drug.
Daily dose
Pharmacokinetic parameters MIC80 (jlg/mU
Drug category Drug (no. of times) ~max TI/2 AUC Protein U UV Utr Cystitis Pyeloneph ritismax(jl mL) (h) (jlg·h/mL) (%) (jlg/mL) (g)
Penicillins PIPC 4 g (2) 98.3 0.78 100.1 7221 3.004 73.46 > 100 12.5
TIPC 3 g (2) 73.0 0.88 161.0 7334 2.1 100.47 > 100 > 100
CVA/TIPC 3.2 g (2) > 100 50
SBT/ABPC 3 g (2) > 100 50
SBTPC 1125 mg (3) > 100 50
Cephalosporins CPM 2 g (2) 154.0 485 0.316 3.15 > 100 > 100
ax 2 g (2) 27.7 2549 1.19 92.02 100 25
CPZ 2 g (2) 125.0 2.67 86.3 651 0.51 5.21 100 100
CAZ 2 g (2) 77.0 1.6 64.2 20.9 3378 1.526 43.87 > 100 > 100
CPIZ 2 g (2) 117.4 1.45 4300 1.542 36.63 > 100 > 100
CDZM 2 g (2) 96.1 2.43 308.0 86.0 1496 1.622 15.57 50 0.78
CPR 2 g (2) 53.0 1.69 111 .4 4965 1.216 93.68 25 50
CZOP 2 g (2) 79.3 1.59 180.0 8.1 2803 1.88 35.35 25 50
Oxacephems LMOX 2 g (2) 85.0 2.2 223.0 2990 1.93 35.18 > 100 > 100
FMOX 2 g (2) 45.2 0.86 66.6 28.5 3258 1.748 72.08 > 100 > 100
Carbapenems IPM/CS 1 g (2) 35.6 0.87 45.3 4337 0.694 121.83 6.25 6.25
PAPM!BP 1 g (2) 27.5 1.19 45.2 7.0 617 0.285 22.44 6.25 3.13
MEPM 1 g (2) 26.9 1.03 33.9 2.4 2098 0.642 77.99 12.5 12.5
Monobactams CRMN 2 g (2) 64.0 1.15 119.6 3826 1.594 59.78 25 6.25
Amino- AMK 400 mg (2) 5.1 1.7 347 0.2812 68.04 > 100 100
glycosides ISP 400 mg (2) 11 .1 1.79 36.1 3.0 559.2 0.338 50.38 100 25
Oral cephems CEX 2 g (2) 13.6 3795 1.98 279.04 > 100 > 100
CCL 1.5 g (3) 13.04 0.5 18.7 2631 1.113 201.76 100 100
CDX 750 mg (3) 6.72 85.2 0.6255 12.68 > 100 > 100
CTM-HE 600 mg (3) 2.06 0.77 5.81 8.0 496.3 0.2298 240.92 > 100 > 100
CFDN 600 mg (3) 1.74 1.78 9.23 73.0 132.2 0.1554 75.98 12.5 3.13
CETB 400 mg (2) 10.4 1.48 43.2 65.2 523.2 0.268 50.31 0.39 25
CFIX 400 mg (2) 1.95 2.29 15.0 63.0 82.7 0.0848 42.41 100 100
CFTM-PI 300 mg (3) 1.11 0.83 3.59 74.6 86.9 0.0687 78.29 > 100 > 100
CPDX-PR 400 mg (2) 2.8 1.9 15.2 30.0 109.9 0.178 39.25 50 50
CFPN-PI 300 mg (3) 1.08 1.1 3.07 114.3 0.1038 105.83 > 100 > 100
CDTR-PI 300 mg (3) 1.66 0.8 3.67 52.66 0.0597 31.72 > 100 3.13
Quinolones PPA 2 g (4) 4.4 1.58 30.0 1116 0.788 253.64 > 100 > 100
NFLX 800 mg (4) 1.15 2.74 4.29 4.3 348 0.3408 302.61 50 12.5
OFLX 600 mg (3) 2.46 4.13 18.7 29.1 285.8 0.4524 116.18 6.25 25
ENX 600 mg (3) 2.2 5.9 9.9 32.0 217 0.3858 98.64 12.5 25
CPFX 600 mg (3) 1.2 3.68 4.59 30.0 255.6 0.2946 213.00 1.56 1.56
LFLX 600 mg (3) 2.12 8.1 13.8 21.4 238.7 0.4086 112.59 25 25
TFLX 450 mg (3) 0.54 4.85 4.95 37.4 64.1 0.1773 118.70 12.5 1.56
FLRX 300 mg (1) 4.16 10.2 57.5 32.0 153 0.1869 36.78 12.5 6.25
SPFX 300 mg (1) 1.2 15.4 16.5 42.2 22.7 0.18 18.92 3.13 0.78
LVFX 300 mg (3) 0.98 3.96 7.46 46.5 235.9 0.2559 240.71 3.13 6.25
C
max
' maximum blood concentration; TI12 , half-life; AUC, area under the curve; Protein, protein binding rate; Umax' maximum urinary
concentration; UV, l-day cumulative urinary excretion; Utr, U jC ; PIPC, piperacillin; TIPC, ticarcillin; CVA/TIPC, c1avulanic
ma ma,.;
acid/ticarcillin; SBT/ABPC, sulbactam/ampicillin; SBTPC, sultamicillin; CPM, cefpiramide; CTX, cefotaxime; CPZ, cefoperazone;
CAZ, ceftazidime; CDZM, cefodizime; CPR, cefpirome; CZOP, cefozopran; LMOX, latamoxef; FMOX, f1omoxef; IPM!CS,
imipenem/cilastatin; PAPM!BP, panipenemlbetamipron; MEPM, meropenem; CRMN, carumonam; AMK, amikacin; ISP, isepamicin;
CEX, cephalexin; CCL, cefaclor; CDX, cefadroxiJ; CTM-HE, cefotiam hexeti/; CFDN, cefdinir; CETB, ceftibuten; CFIX, cefixime;
CETM-PI, cefteram pivoxi/; CPDX-PR, cefpodoxime proxetil; CFPN-PI, cefcapene pivoxil; CDTR-PI, cefditoren pivoxil; PPA,
pipemidic acid; NFLX, norfloxacin; OFLX, ofloxacin; ENX, enoxacin; CPFX, ciprofloxacin; LFLX, lomefloxacin; TFLX, tosufloxacin;
FLRX, fleroxacin; SPFX, sparfloxacin; LVFX, levofloxacin.
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Table 2. Correlation coefficients' among pharmacokinetic parameters, MICaa' daily dose, and empiric breakpoint (BP).
Item 2 3 4 5 6 7 8 9
1 log (Cm.) -0.4010 0.9130 0.9044 0.8734 -0.3659 0.1985 0.8321 0.5515
2 T'/2 0.0254 -0.0839 -0.5196 -0.2498 -0.1956 -0.4294 -0.3591 -0.2496
3 log (AUC) near 0 0.6537 0.7418 0.8124 -0.5172 -0.0022 0.7284 0.4659
4 log (Urn.) near 0 0.0027 near 0 0.9164 0.0661 0.2083 0.8428 0.5820
5 log (UV) near 0 0.1753 near 0 near 0 -0.0436 0.1087 0.8822 0.5547
6 log (Utr) 0.0430 0.2917 0.0029 0.7237 0.8157 --.0.0101 -0.1076 -0.0201
7 MIC80 0.2843 0.0159 0.9904 0.2609 0.5607 0.9572 0.3719 0.0263
8 Daily dose near 0 0.0472 near 0 near 0 near 0 0.5646 0.0394 0.3756
9 log (BP) 0.0013 0.1757 0.0083 0.0006 0.0012 0.9145 0.8882 0.0373
m.x
0.913 log (AUC)
0.904 0.742 log (U
m
.)
0.873 0.812 0.916 I log (UV)
0.832 0.728 0.843 I 0.882 I
'Correlation matrix: upper right, correlation coefficients; lower left, P value for statistics to test whether population correlation
coefficient is zero or not.
Correlation coefficients among 5 items
log (e )
log (AUC)
log (U
m
.)
log (UV)
daily dose
Table 3. Results of categoric regression analysis.
Item Category Freq (Prop) RC PCC Range
TypeN
< 1 8 (0.258) -0.341 0.174 0.460
T'/2 1 to < 2 11 (0.355) 0.118(hour) ~2 12 (0.387) 0.119
< 100 5 (0.161 ) -0.788 0.320 1.487
100 to < 300 9 (0.290) -0.122
U 300 to < 1000 5 (0.161) -0.414
max(Jig/mL) 1000 to < 3000 5 (0.161) 0.699
~ 3000 7 (0.226) 0.516
M1C80 < 50 16 (0.516) 0.097 0.089 0.201(Jig/mU ~ 50 15 (0.484) -0.104
Drug Oral drugs 19 (0.613) -0.444 0.340 1.147
profile Parenteral drugs 12 (0.387) 0.703
Constant 2.459
Type Bb
< 1 8 (0.258) -0.459 0.265 0.865
T'/2 1 to < 2 11 (0.355) -0.109(hour) ~2 12 (0.387) 0.406
< 100 5 (0.161) -0.895 0.368 1.525
100 to < 300 9 (0.290) -0.111
U 300 to < 1000 5 (0.161 ) -0.395
m.x
(Jig/mU 1000 to < 3000 5 (0.161) 0.603
~ 3000 7 (0.226) 0.630
MIC80 < 50 16 (0.516) 0.208 0.195 0.429
(Jig/mU ~ 50 15 (0.484) -0.222
Drug Oral quinolones 9 (0.290) -0.875 0.382c 1.650
profile Oral cephems 10 (0.323) -0.141
Parenteral drugs 12 (0.387) 0.774
Constant 2.459
Freq (Prop), frequency (proportion); RC, estimated regression coefficient; PCC, partial correlation coefficient.
'Contribution ratio, 0.51 09; multiple correlation coefficient, 0.7148; sample size, 31; bcontribution ratio, 0.5186; cp
< 0.05; multiple correlation coefficient, 0.7202; sample size, 31.
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Table 4. Regression coefficients estimated with categoric regression analysis, and their rounded values.
Mean BP Type A Type B
Item Category (log scale) b exp(b) C b exp(b) C
Tl/~ < 1 2.265 -0.341 0.711 0.5 -0.459 0.632 0.5
(hour) 1 to < 2 2.904 0.118 1.125 1.0 -0.109 0.897 1.0
;::2 2.179 0.119 1.126 1.0 0.460 1.501 1.5
U < 100 1.138 -0.788 0.455 0.5 -0.895 0.409 0.5max
CUglmU 100 to < 300 2.064 -0.122 0.885 0.5 -0.111 0.895 0.5
300 to < 1000 1.833 -0.414 0.661 0.5 -0.395 0.674 0.5
1000 to < 3000 3.635 0.699 2.012 2.0 0.608 1.837 2.0
;:: 3000 3.516 0.516 1.675 2.0 0.630 1.878 2.0
MIC60 < 50 2.612 0.097 1.102 1.0 0.208 1.231 1.0
CUglmL) ;:: 50 2.094 -0.104 0.901 1.0 -0.222 0.801 1.0
Drug profi Ie Oral quinolones 1.833
-0.444 0.641 0.5 -0.875 0.417 0.5Oral cephems 1.624 -0.141 0.868 1.0
Parenteral drugs 3.623 0.703 2.020 2.0 0.774 2.168 2.0
Constant 2.459 11.693 12.0 2.459 11.693 12.0
BP, empiric breakpoint; b, regression coefficient; C, rounded value.
Calculation formula for a breakpoint
logy =bo+ b1xxi + ... + b4 xX4
Y=exp(bo+ b l x XI + ... + b4 x x 4)
=exp(bO> exp(bl x Xl) ... Exp(b4 x X4)
=Co . C, . C2 • C3 • C4 (constant x Tin X Umax X MIC60 x drug profile)
the breakpoint of piperacillin (PIPC) for type A is as
follows. The constant term is 2 in this case. T1/Z and
Umax ofPIPC are 0.78 hour and 7221 f.lg/mL (Table 1),
and the rounded values corresponding to these are 0.5
and 2 (Table 4), respectively. As PIPC is a parenteral
drug, it gets 2 for drug profile value. From these values,
the predicted breakpoint ofPIPC = constant x Tl/Z X Umax
x drug profile (type A) =12 x 0.5 x 2 x 2 =24 f.lg/mL.
To examine deviation between the predicted break-
points and the empiric breakpoints, logz (empiric break-
point/predicted breakpoint) was calculated for all 31
drugs. The result (Table 5) showed that the average de-
viations calculated for all the drugs were 1.481 tube in
type A and 1.297 tube in type B. The deviation was
slightly smaller in type B than in type A. Therefore, we
decided to adopt type B as the calculation formula for
predicted breakpoints of antimicrobial agents for com-
plicated urinary tract infections (Table 6). Finally, we
replaced the resulting predicted breakpoints with ones
having the nearest (not higher than but most close) value
to the gradient MIC indications by the agar plate dilu-
tion method or by the National Committee for Clinical
Laboratory Standards (NCCLS) method. For 4 drugs
that were excluded in the examination, the pharmacoki-
netic parameters have been observed and their predicted
breakpoints based on the formula are also shown as ref-
erences (Table 5, bottom row).
Examination of breakpoints ofantimicrobial agents
for complicated pyelonephritis
In complicated pyelonephritis, empiric breakpoints were
established on the basis of the cross tables between the
baseline MIC values and bacteriologic response of anti-
microbial agents, using the method similar to the one
adopted for complicated cystitis presented in our first
report. However, in most ofthe clinical trials, the number
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Table 5. Empiric breakpoint and estimated breakpoint for each antimicrobial agent.
Type A Type B Type B
Drug category Drug BP,a BP/ BP, vs. BP/ BP/ BP, vs. BPzc APD method
d NCClS method
(,U!1/mL) (,ug/mLl (,U!1/mL) Bp
3
b BP, vs. BP3c BP.b BP, vs. BP.c(,U!1/mL) (,U!1/ml)
Penicillins PIPC 6.25 24 -1.941 24 -1.941 12.5 -1.000 16 -1.356
TIPC 6.25 24 -1.941 24 -1.941 12.5 -1.000 16 -1.356
Cephalosporins CAZ 100 48 1.059 48 1.059 25 2.000 32 1.644
CDZM 12.5 48 -1.941 72 -2.526 50 -2.000 64 -2.356
CPR 12.5 48 -1.941 48 -1.941 25 -1.000 32 -1.356
CZOP 50 48 0.059 48 0.059 25 1.000 32 0.644
Oxacephems lMOX 100 48 1.059 72 0.474 50 1.000 64 0.644
FMOX 100 24 2.059 24 2.059 12.5 3.000 16 2.644
Carbapenems IPM/CS 100 24 2.059 24 2.059 12.5 3.000 16 2.644
PAPM/BP 25 12 1.059 12 1.059 6.25 2.000 8 1.644
MEPM 100 48 1.059 48 1.059 25 2.000 32 1.644
Monobactams CRMN 100 48 1.059 48 1.059 25 2.000 32 1.644
Aminoglycosides ISP 1.56 12 -2.943 12 -2.943 6.25 -2.002 8 -2.358
Oral cephems CCl 12.5 6 1.059 12 0.059 6.25 1.000 8 0.644
CTM-HE 25 1.5 4.059 3 3.059 1.56 4.002 2 3.644
CFDN 6.25 3 1.059 6 0.059 3.13 0.998 4 0.644
CElB 3.13 3 0.061 6 4).939 3.13 0.000 4 4).354
CFlX 12.5 3 2.059 9 0.474 6.25 1.000 8 0.644
CFTM-PR 0.78 1.5 4).943 3 -1.943 1.56 -1.000 2 -1.358
CPDX-PR 6.25 3 1.059 6 0.059 3.13 0.998 4 0.644
CFPN-PI 25 3 3.059 6 2.059 3.13 2.998 4 2.644
CDTR-PI 0.78 1.5 4).943 3 -1.943 1.56 -1.000 2 -1.358
Quinolones NFLX 3.13 3 0.061 4.5 4).524 3.13 0 4 4).354
OFlX 6.25 3 1.059 4.5 0.474 3.13 0.998 4 0.644
ENX 6.25 3 1.059 4.5 0.474 3.13 0.998 4 0.644
CPFX 3.13 3 0.061 4.5 4).524 3.13 0 4 4).354
LFlX 12.5 3 2.059 4.5 1.474 3.13 1.998 4 1.644
TFlX 25 3 3.059 4.5 2.474 3.13 2.998 4 2.644
FlRX 12.5 3 2.059 4.5 1.474 3.13 1.998 4 1.644
SPFX 1.56 3 4).943 4.5 -1.528 3.13 -1.005 4 -1.358
LVFX 6.25 3 1.059 4.5 0.474 3.13 0.998 4 0.644
Average of absolute deviations 1.481 1.297 1.516 1.413
Other drugs CPZ 1.56 12 -2.943 18 -3.528 12.5 -3.002 16 -3.358
CPIZ 12.5 48 -1.941 48 -1.941 25 -1.000 32 -1.356
AMK 3.13 12 -1.939 12 -1.939 6.25 4).998 8 -1.354
PPA 25 12 1.059 12 1.059 6.25 2.000 8 1.644
aBP" empiric breakpoint; BP2, estimated breakpoint; bBP3 and BP., predicted breakpoints with one of the nearest (not higher than but
most close) value of gradient MIC indication by APD method and National Committee for Clinical laboratory Standards method,
respectively; cBP I vs. BP2, BPI vs. BP3• and BP, vs. BP. means logz(BP/BP2), log2(BP/BP3) and logz(BP/BP.), respectively; dAPD, agar
plate dilution. Drug names as in Table 1.
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Table 6. Calculation formula for breakpoint of antimicrobial
agents in complicated cystitis.
Breakpoint = constant x T1/2 X Umax x drug profile
Item
T1/2 (hour)
Drug profile
Constant
Category Rounded value
< 1 0.5
1 to < 2 1.0
~ 2 1.5
< 1000 0.5
~ 1000 2.0
Oral quinolones 0.5
Oral cephems 1.0
Parenteral drugs 2.0
12.0
Table 7. Difference between empiric breakpoints for complicated cystitis and empiric breakpoints for complicated pyelonephritis.
Drug category Drug
Complicated cystitis Complicated pyelonephritis Difference
No. of strain Area" BP,b (JLg!mL) No. of strain Area" BP/{JLg!mL) log2(BP,IBP)
Penicillins PIPC 130 0.702 6.25 31 0.795 3.13 0.998
TIPC 124 0.679 6.25 59 0.654 6.25 0.000
CVN'fIPC 126 0.659 100 31 0.828 50 1.000
Cephalosporins CPM 196 0.709 25 65 0.742 3.13 2.998
CPZ 464 0.706 1.56 164 0.775 1.56 0.000
CAl 571 0.725 100 202 0.796 100 0.000
CDZM 78 0.757 12.5 24 0.826 3.13 1.998
Oxacephems FMOX 124 0.764 100 47 0.922 50 1.000
Carbapenems PAPM/BP 121 0.717 25 43 0.775 3.13 2.998
Monobactams CRMN 101 0.813 100 54 0.609 6.25 4.000
Aminoglycosides ISP 148 0.744 1.56 47 0.775 6.25 -2.002
Oral cephems CETB 78 0.962 3.13 29 0.655 25 -2.998
CFIX 252 0.81 12.5 53 0.820 0.78 4.002
Quinolones PPA 236 0.832 25 58 0.766 3.13 2.998
NFLX 379 0.819 3.13 115 0.845 1.56 1.005
OFLX 393 0.864 6.25 112 0.898 12.5 -1.000
ENX 246 0.843 6.25 63 0.842 3.13 0.998
CPFX 135 0.934 3.13 42 0.957 1.56 1.005
TFLX 164 0.889 25 41 0.818 6.25 2.000
FLRX 138 0.9 12.5 41 0.850 12.5 0.000
SPFX 151 0.944 1.56 34 0.883 3.13 -1.005
LVFX 150 0.927 6.25 40 0.950 12.5 -1.000
Average 0.863
"Area, area under the receiving operator characteristic curve; bBPI' BP2, empiric breakpoint. Drug names as in Table 1.
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of patients with complicated pyelonephritis was ex-
tremely small and it was impossible to determine the
empiric breakpoints. Here, the empiric breakpoints for
complicated pyelonephritis were determined for 22 an-
timicrobial drugs, excluding the drugs whose trials had
less than 20 isolated bacterial strains measured, whose
trials had the area under the ROC (receiver operating
characteristic) curve of less than 0.6, and whose trials
did not show a definite tendency in the eradication rate
with respect to MIC.
We attempted to construct a calculation formula for
predicted breakpoints by using the analysis similar to
the one for complicated cystitis, but we were not satis-
fied with the results due to the small number ofpatients.
As the second-best policy, we explored the possibility of
establishing breakpoints for complicated pyelonephritis
by comparison with those for complicated cystitis.When
the differences in the empiric breakpoints of 22 drugs
between complicated pyelonephritis and complicated
cystitis, that is, the logz (empiric breakpoints for com-
plicated cystitis/empiric breakpoints for complicated
pyelonephritis) was calculated, the mean standard de-
viation of the difference became 0.86 3 ± 1.859 in the
tubes (Table 7). Consequently, we decided to estimate
breakpoints for complicated pyelonephritis by subtract-
ing 1 (tube, ie, one-half value) from those for compli-
cated cystitis (Table 5).
Predicted breakpoints for various antimicrobial agents
determined by the procedure described above are sum-
marized in Table 8.
Table 8. Estimated breakpoints.
Daily
Breakpoint MIC (J1WmL)
Drug category Drug Route C-pyelonephritisdose Estimated BP C-cystitisNCCLS method NCCLS method
Penicillins PIPC IV 2gx2 24 16 8
TIPC IV 1.5 g x 2 24 16 8
Cephalosporins CAZ IV 1 g x2 48 32 16
CDZM IV 1 g x 2 72 64 32
CPR IV 1 gx2 48 32 16
CZOP IV 1 gx2 48 32 16
CPZ IV 1 gX2 18 16 8
CPIZ IV 19x2 48 32 16
Oxacephems LMOX IV 19x2 72 64 32
FMOX IV 1 g x 2 24 16 8
Carbapenems IPM!CS IV 0.5 g x 2 24 16 8
PAPM!BP IV 0.5 g x 2 12 8 4
MEPM IV 0.5 g x 2 48 32 16
Monobactams CRMN IV 19x2 48 32 16
Aminoglycosides AMK 1M 200 mgx2 12 8 4
ISP • 1M 200 mgx2 12 8 4
Oral cephems CCL PO 500 mg x 3 12 8 4
CTM-HE PO 200 mg x 3 3 2 1
CFDN PO 200 mg x 3 6 4 2
CETB PO 200 mgx2 6 4 2
CFIX PO 200 mg x 2 9 8 4
CFTM-PI PO 100 mg x 3 3 2 1
CPDX-PR PO 200 mgx2 6 4 2
CFPN-PI PO 100 mgx3 6 4 2
CDTR-PI PO 100 mgx3 3 2 1
Quinolones PPA PO 500 mgx4 12 8 4
NFLX PO 200 mgx4 4.5 4 2
OFLX PO 200 mgx3 4.5 4 2
ENX PO 200 mg x3 4.5 4 2
CPFX PO 200 mgx3 4.5 4 2
LFLX PO 200 mg x 3 4.5 4 2
TFLX PO 150 mgx3 4.5 4 2
FLRX PO 300 mg xl 4.5 4 2
SPFX PO 300 mg xl 4.5 4 2
LVFX PO 100 mg x3 4.5 4 2
C-cystitis, complicated cystitis; C-pyelonephritis, complicated pyelonephritis; NCCLS, National Committee for Clinical
Laboratory Standards. Drug names as in Table 1.
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DISCUSSION
In this study, empiric breakpoints were characterized
by pharmacokinetic parameters leading to a formula to
calculate the empiric breakpoints by combination oftypi-
cal parameters and, then, predicted breakpoints were
determined for the purpose and necessity stated below.
Empiric breakpoints have been established from the
results of particular clinical trials. Because the numbers
of patients in these trials are restricted, we cannot say
positively that these empiric breakpoints based on their
results represent true breakpoints of the drugs con-
cerned. This means that the given empiric breakpoint is
clinically applicable only when the number of eligible
patients in the clinical trial is large enough for analysis
and the MIC distributions of the causative bacteria iso-
lated from the patients are universal for the drug con-
cerned, however, this is not always the actual case.Thus,
to obtain more generalized breakpoints, it is necessary
to construct a model using statistical techniques with
objective parameters, such as its characteristics, antimi-
crobial activity, tissue distribution, urinary and blood
concentrations and half-life, taking account of empiric
breakpoints of many antimicrobial agents, and to pre-
dict the breakpoint of the antimicrobial agent based on
the constructed model. However, it must be stated clearly
as an incidental matter that the breakpoints predicted
by the above method cannot be applied as they are to
the cases with particular factors such as renal dysfunc-
tion or Pseudomonas infections or those relating to host
immunodeficiency. Once a calculation formula is con-
structed on the basis of pharmacokinetic parameters,
the breakpoint of a new drug under development can
be predicted using the parameters observed in the phase
I trial prior to the start ofclinical trials and, therefore, it
may be referred to for establishing an optimum dosage.
While breakpoints of antimicrobial agents have al-
ready been established in the United States and the
United Kingdom,3-s they are not restricted to particu-
lar diseases. However, with regard to pharmacokinetic
parameters of antimicrobial agents, urinary concentra-
tion is important in urinary tract infections, and tissue
and blood concentrations are important in respiratory
tract infections, and breakpoints must naturally differ
between these disease groups. In addition, it is ques-
tionable to apply the breakpoints of the patients inWest-
ern countries to those in Japan because ofthe differenc~s
in the dosageltime and pharmacokinetics of the drugs.
From these viewpoints, original breakpoints have been
set up for respiratory tract infections and septicemia in
Japan6 and, subsequently, the necessity of setting up
breakpoints of antimicrobial agents for urinary tract in-
fections has been advocated. Therefore, it is an impor-
tant proposition to deduce a calculation formula for
breakpoints of antimicrobial agents for urinary tract in-
fections based on the scientific analysis of clinical study
results and to verify usefulness of the formula. This atti-
Calculation formula for breakpoints in UTI
tude would contribute greatly to the evaluation of anti-
microbial agents and their proper uses.
The predicted breakpoints deduced logically using
statistical techniques in this study are considered ap-
propriate, since they have been derived from the calcu-
lation formula determined on the basis ofcomprehensive
data of nearly 50 antimicrobial agents developed in the
past 10 years. Yet, these breakpoints are not without limi-
tations, and they have several problems.
Breakpoints with respect to bacterial species
In infections established in a local or systemic pathologic
state, particularly in Pseudomonas infections, host con-
ditions, such as immunologic competence to resist in-
fections, differ from those in healthy persons.Therefore,
breakpoints calculated by the formula deduced from the
present basic data (empiric breakpoints), the majority
ofwhich is a collection ofclinical study results ofstand-
ard bacterial infections, are not applicable uniformly to
infections occurring under particular pathologic condi-
tions. In fact, the US NCCLS3,4 has established break-
points for Pseudomonas infections as a separate category.
To solve this problem, it is conceivable to extract the
results in the group of Pseudomonas infections from the
existing comparative study results, subject them to an
analysis similar to the present one, and construct a cal-
culation formula exclusively for them. However, this is
difficult to put into practice, due to the small numbers
ofPseudomonas cases.This is a problem that will need to
be addressed.
Drug profile
For the present calculation formula, 3 categories, oral
quinolones, oral cephems, and parenteral drugs, were
used, and the rounded values of 0.5, 1.0, and 2.0 were
calculated, respectively. These values were deduced by
the statistical techniques on the basis of the relationship
between empiric breakpoints and pharmacokinetic pa-
rameters, and their relationship to antimicrobial activi-
ties (presence or absence of PAE, bactericidal potency,
bacteriostatic action, etc.) are not explained at present.
Moreover, which rounded value should be used when a
completely new type of drug is developed in the future
remains a problem.
Method for presenting predicted breakpoints
The predicted breakpoints calculated from the present
formula are not expressed in values of 2-fold series. In
other words, they are expressed differently from those
of the MIC expression of the agar-plate dilution method
or NCCLS indications. Therefore, to refer predicted
breakpoints to these conventional MIC expressions, it
is necessary to "apply" a conventional MIC that is not
greater than, yet is most close to, the calculated value.
For convenience, the converted values in the agar-plate
dilution method and the NCCLS method are also given
separately from the predicted breakpoints in this report
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(Table 5). However, it may be appropriate to convert
the breakpoints in the present study into the MIC ex-
pression by the agar-plate dilution method, since our
calculation formula was analyzed and deduced from the
basic data indicated by this expression. Only the values
corresponding to the MIC of the NCCLS method are
given in the attached table taking the international har-
monization into consideration.
Calculation formula for the breakpoints in
complicated pyelonephritis
We also examined a calculation formula for breakpoints
in complicated pyelonephritis by using the same proc-
ess as that for complicated cystitis in an attempt to con-
struct it. But the number of patients with this disease
was too small to do an appropriate statistical analysis.
Therefore, construction of a calculation formula in
pyelonephritis with the same quality as that for compli-
cated cystitis was judged impossible at this point. How-
ever, because the kidneys and the bladder have common
urinary flows, the distribution of causative bacteria and
indicated drugs are almost the same in the 2 diseases.
Moreover, because the correlation coefficients between
the drugs examined in complicated pyelonephritis and
pharmacokinetic parameters resemble those in compli-
cated cystitis (concrete data is not shown), it is not theo-
retically inconsistent to apply the same parameters in
complicated cystitis to a calculation formula in compli-
cated pyelonephritis.Thus, it was judged as permissible
to set up the breakpoints for complicated pyelonephri-
tis by adding some modifications to the breakpoints for
complicated cystitis. From this standpoint, the empiric
breakpoints ofthe respective drugs in the 2 diseases were
compared and found to have a difference of about 1
tube, on the average. Hence, the predicted breakpoints
in complicated pyelonephritis were set as 1 tube smaller
than those predicted by the calculation formula for com-
plicated cystitis. •
Conclusion
A calculation formula for breakpoints should be deduced
essentially on the basis of the results of clinical studies
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conducted with the purpose of its construction using
adequate statistical techniques. To perform a truly ob-
jective analysis, the ideal would be to use the basic data
obtained from the results of studies conducted with the
same subject population and the same infectious dis-
ease by using the respective antimicrobial agents. How-
ever, this is not realistic, and the most practical way is to
use the clinical study results accumulated in the past.
The calculation formula derived in this study has some
problems that need to be solved, but it was statistically
determined so as not to contradict actual clinical prac-
tice based on versatile statistical analyses of vast data
from clinical trials ofurinary tract infections conducted
in the past 10 years in Japan. We hope that breakpoints
for new drugs will be established according to our cal-
culation formula, and that the formula will be validated
and modified by comparing it to calculated breakpoints.
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